Skip to main content
. 2018 Jul 6;10(7):359. doi: 10.3390/v10070359

Figure 1.

Figure 1

Fused-in-sarcoma (FUS) represses Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation in primary effusion lymphoma (PEL) cells. (A) Western blot analysis of FUS expression 48 h post reactivation in TREx-BCBL1-RTA cells treatmented with the indicated siRNAs. Knockdown efficiency is indicated beneath each lane. (B) RT-qPCR of viral transcripts from cells in (A). All samples were normalized to 18S and siCon levels set to 1. (C) Western blot of viral proteins from cells in (A). (D) TREx-BCBL1-RTA cells were transfected with the indicated siRNAs for 18 h prior to RNA isolation and RT-qPCR. All samples were normalized to 18S and siCon levels set to 1. (E) TREx-BCBL1-RTA cells were depleted of FUS for 18 h, followed by reactivation with doxycycline and sodium butyrate for 48 h. Virus and cells were centrifuged, viral genomes present were determined as described in the methods.. All samples were normalized to GAPDH, and siCon set to 1. Student t test used to determine statistical significance * p ≤ 0.05. ** p ≤ 0.005. *** p ≤ 0.0005, n.s. not significant.